Healthcare
Eli Lilly and Company(LLY)
Live Price
Offline$1,098.57
-1.21% today
1Y Change
+47.02%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $915.33B
- Revenue Growth
- +44.7%
- EPS Growth
- +95.6%
- Dividend Yield
- 0.6%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eli Lilly and Company (LLY) is a Healthcare stock with a market cap of $915.33B and listed on NYSE. The stock last traded around $1098.57 and up 47.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +44.7%, EPS growth of +95.6%, a dividend yield of 0.6%. What stands out right now is revenue +44.7%, EPS +95.6%, free cash flow +2065.6% with operating margin 45.9% and ROIC 32.1%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 34.3 and price/sales 12.7. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines LLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+44.7% vs +7.6% peer median
Operating Margin
Above sector median
+45.9% vs +19.4% peer median
P/E
Below sector median
34.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +44.7% and EPS at +95.6%, with operating margin around 45.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 30, 2026 | โ | +3.1% | +4.3% | +18.2% |
2026 Feb 4, 2026 | +9.1% | -7.8% | -8.3% | -11.2% |
2025 Oct 30, 2025 | +23.4% | +2.2% | +11.0% | +27.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
LLY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
LLY Max Drawdown
-23.31%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LLY and SPY.
Company Overview
Eli Lilly and Company
New York Stock Exchange
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Leadership
- David A. Ricks
- IPO Date
- Jun 1, 1972
- Employees
- 47.0k
- Street Address
- Lilly Corporate Center
- Mailing
- Indianapolis, IN, 46285
- Region
- Indianapolis, IN, US
- Reporting Currency
- USD
- Investor Line
- 317 276 2000
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 34.3
- EV/EBITDA
- 28.8
- Price/Sales
- 12.7
- Price/Book
- 27.8
Growth
- Revenue
- +44.7%
- EPS
- +95.6%
- Free Cash Flow
- +2065.6%
Profitability
- Gross Margin
- 83.5%
- Operating Margin
- 45.9%
- Net Margin
- 35.0%
- ROE
- 101.3%
- ROIC
- 32.1%
Balance Sheet
- Debt/Equity
- 1.39
- Current Ratio
- 1.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.